Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth in a mouse mammary gland cancer cell line

Cancer Letters

Volumn 288, Issue 2, 2010, Pages 219-225

  Foreman, Jennifer E ^a   Sharma, Arun K ^b   Amin, Shantu ^b   Gonzalez, Frank J ^c   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cell proliferation; Mammary gland cancer; Peroxisome proliferator activated receptor

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANGIOPOIETINS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIGANDS; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; PPAR DELTA; PPAR-BETA; THIAZOLES; TIME FACTORS; TUMOR STEM CELL ASSAY;

EID: 74849089577     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.07.006     Document Type: Article

References (33)

1. Lee C.H., Olson P., and Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144 (2003) 2201-2207
2. Goldenberg I., Benderly M., and Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc. Health Risk Manage. 4 (2008) 131-141
3. Peters J.M., Cheung C., and Gonzalez F.J. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?. J. Mol. Med. 83 (2005) 774-785
4. Chiarelli F., and Di Marzio D. Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc. Health Risk Manage. 4 (2008) 297-304
5. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43 (2000) 527-550
6. Pelton P. GW-501516 GlaxoSmithKline/Ligand. Curr. Opin. Investig. Drugs 7 (2006) 360-370
7. Burdick A.D., Kim D.J., Peraza M.A., Gonzalez F.J., and Peters J.M. The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal 18 (2006) 9-20
8. Muller R., Rieck M., and Muller-Brusselbach S. Regulation of Cell Proliferation and Differentiation by PPARβ/δ. PPAR Res. 2008 (2008) 614852
9. Peters J.M., Hollingshead H.E., and Gonzalez F.J. Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin. Sci. (Lond.) 115 (2008) 107-127
10. Peters J.M., and Gonzales F.J. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim. Biophys. Acta (2009) 10.1016/j.bbcan.2009.06.002
11. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98 (2001) 5306-5311
12. Luquet S., Lopez-Soriano J., Holst D., Gaudel C., Jehl-Pietri C., Fredenrich A., and Grimaldi P.A. Roles of peroxisome proliferator-activated receptor δ (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 86 (2004) 833-837
13. Kilgore K.S., and Billin A.N. PPARβ/δ ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9 (2008) 463-469
14. Borland M.G., Foreman J.E., Girroir E.E., Zolfaghari R., Sharma A.K., Amin S.M., Gonzalez F.J., Ross A.C., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) Inhibits cell proliferation in human HaCaT keratinocytes. Mol. Pharmacol. 74 (2008) 1429-1442
15. Kim D.J., Murray I.A., Burns A.M., Gonzalez F.J., Perdew G.H., and Peters J.M. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem. 280 (2005) 9519-9527
16. Peraza M.A., Burdick A.D., Marin H.E., Gonzalez F.J., and Peters J.M. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 90 (2006) 269-295
17. Stephen R.L., Gustafsson M.C., Jarvis M., Tatoud R., Marshall B.R., Knight D., Ehrenborg E., Harris A.L., Wolf C.R., and Palmer C.N. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. 64 (2004) 3162-3170
18. Aung C.S., Faddy H.M., Lister E.J., Monteith G.R., and Roberts-Thomson S.J. Isoform specific changes in PPARα and β in colon and breast cancer with differentiation. Biochem. Biophys. Res. Commun. 340 (2006) 656-660
19. Girroir E.E., Hollingshead H.E., Billin A.N., Willson T.M., Robertson G.P., Sharma A.K., Amin S., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology 243 (2008) 236-243
20. Ghosh M., Ai Y., Narko K., Wang Z., Peters J.M., and Hla T. PPARδ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostag. Oth. Lipid M. 88 (2009) 97-100
21. Yin Y., Russell R.G., Dettin L.E., Bai R., Wei Z.L., Kozikowski A.P., Kopleovich L., and Glazer R.I. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 65 (2005) 3950-3957
22. Chang S.H., Liu C.H., Wu M.T., and Hla T. Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostag. Oth. Lipid M. 76 (2005) 48-58
23. Girroir E.E., Hollingshead H.E., He P., Zhu B., Perdew G.H., and Peters J.M. Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem. Biophys. Res. Commun. 371 (2008) 456-461
24. He P., Borland M.G., Zhu B., Sharma A.K., Amin S., El-Bayoumy K., Gonzalez F.J., and Peters J.M. Effect of ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in human lung cancer cell lines. Toxicology 254 (2008) 112-117
25. Franken N.A., Rodermond H.M., Stap J., Haveman J., and van Bree C. Clonogenic assay of cells in vitro. Nature protocols 1 (2006) 2315-2319
26. De Wever O., and Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 200 (2003) 429-447
27. Chang S.H., Liu C.H., Conway R., Han D.K., Nithipatikom K., Trifan O.C., Lane T.F., and Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. USA 101 (2004) 591-596
28. Sznaidman M.L., Haffner C.D., Maloney P.R., Fivush A., Chao E., Goreham D., Sierra M.L., LeGrumelec C., Xu H.E., Montana V.G., Lambert M.H., Willson T.M., Oliver W.R., and Sternbach D.D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13 (2003) 1517-1521
29. Kim D.J., Bility M.T., Billin A.N., Willson T.M., Gonzalez F.J., and Peters J.M. PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13 (2006) 53-60
30. Foreman J.E., Sorg J.M., McGinnis K.S., Rigas B., Williams J.L., Clapper M.L., Gonzales F.J., and Peters J.M. Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal anti-inflammatory drugs. Mole Carcinogen (2009) 10.1002/mc.20546
31. He T.C., Chan T.A., Vogelstein B., and Kinzler K.W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99 (1999) 335-345
32. Narko K., Zweifel B., Trifan O., Ristimaki A., Lane T.F., and Hla T. COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostag. Oth. Lipid M. 76 (2005) 86-94
33. Müller-Brüsselbach S., Kömhoff M., Rieck M., Meissner W., Kaddatz K., Adamkiewicz J., Keil B., Klose K.J., Moll R., Burdick A.D., Peters J.M., and Müller R. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO J. 26 (2007) 3686-3698